14.03.2017
STRATEC Biomedical AG DE000STRA555
DGAP-News: STRATEC reports its preliminary results for 2016
DGAP-News: STRATEC Biomedical AG / Key word(s): Preliminary Results
STRATEC reports its preliminary results for 2016
14.03.2017 / 07:29
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
STRATEC reports its preliminary results for 2016
- Sales of EUR 184.9 million (+25.9%; previous year: EUR 146.9 million)
- EBIT of EUR 32.2 million* (+19.7%; previous year: EUR 26.9 million)
- EBIT margin at 17.4%* (previous year: 18.3%)
- Dividend proposal planned to be increased to EUR 0.77 per share (previous
year: EUR 0.75)
* figures adjusted for one-off items resulting from transaction activities
and related reorganization expenses
Birkenfeld, March 14, 2017
STRATEC Biomedical AG (Frankfurt: SBS; Prime Standard) today announces
preliminary unaudited figures for the 2016 financial year for the STRATEC
Group.
STRATEC Biomedical AG concluded the 2016 financial year on a successful
note. The company generated sales of EUR 184.9 million, exceeding its
previously announced sales forecast for 2016 of between EUR 175 million and
EUR 182 million. The EBIT margin of 17.4% achieved by the company was at the
upper end of the forecast corridor of 16.0% to 17.5%. EBIT came to EUR 32.2
million, compared to EUR 26.9 million in the previous year. These earnings
figures have been adjusted to exclude one-off items of EUR 8.0 million
(9M/2016: EUR 6.7 million) for transaction and integration activities in
connection with the two company takeovers executed in 2016. Despite the
substantial benefits of scale recently achieved and the associated positive
impact on the company's margin performance, STRATEC nevertheless sees
opportunities for a further slight improvement in its operating margin.
In the 2017 financial year, the two companies acquired in 2016 will both be
consolidated in the STRATEC Group for the first full reporting period. In
this context, STRATEC will continue with its reorganization measures across
the whole Group for which further investments (in particular IT) of a total
amount of around EUR 4 million have been planned over the three coming
years. This process has also involved and will continue to involve
restructuring sections of previously existing business units.
Comments Marcus Wolfinger, CEO of STRATEC: "We are very satisfied with our
operating performance, which was driven by the pleasing performance of our
new subsidiaries and slight organic growth. The initial integration phase is
now complete and the first signs of joint success and synergies are already
apparent. As was often the case in STRATEC's past, notwithstanding the
long-term nature of our customer relationships the seasonal variations in
our business performance were often very marked. This means that our
performance within a given financial year often does not follow a linear
trajectory. We witnessed this once again in the past financial year, with
its very strong fourth quarter. We expect a similar development in the
quarters ahead. Given pending market approvals and synergy effects from the
acquisitions, we are very optimistic about the company's further growth."
An update of the financial guidance figures is expected to be released upon
the publication of the Half-Year Financial Report on July 25, 2017. Until
then, the existing guidance remains valid.
At the meeting due to be held to approve the financial statements, the Board
of Management and Supervisory Board will discuss what could be the 13th
consecutive increase in the dividend proposal to the Annual General Meeting.
For the 2016 financial year, the dividend rise to EUR 0.77 per share will be
discussed (previous year: EUR 0.75).
STRATEC will publish its definitive, audited figures for the 2016 financial
year on April 20, 2017.
Conference call and audio webcast
To comment on the preliminary results STRATEC will hold a short conference
call in English today, Tuesday, March 14, 2017 at 3.00 p.m. (CET).
The access information (telephone number, passcode + individual PIN) will be
provided once the participant has registered at this link:
www.stratec.com/registration
The conference call may also be followed as an audio webcast at
www.stratec.com/audiowebcast20170314 (brief registration required). Please
note that it is not possible to submit any questions via the audio webcast.
You can also follow and/or download the slide presentation via this link.
About STRATEC
STRATEC Biomedical AG ( www.stratec.com) designs and manufactures fully
automated analyzer systems for its partners in the fields of clinical
diagnostics and biotechnology. Furthermore, the company offers sample
preparation solutions, integrated laboratory software, and complex
consumables for diagnostic and medical applications. STRATEC covers the
entire value chain - from development to design and production through to
quality assurance.
The partners market the systems, software and consumables in general
together with their own reagents, as system solutions to laboratories, blood
banks and research institutes around the world. STRATEC develops its
products on the basis of its own patented technologies.
Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard
segment of the Frankfurt Stock Exchange.
Further information can be obtained from:
STRATEC Biomedical AG
André Loy, Corporate Communications
Gewerbestr. 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916-190
Fax: +49 7082 7916-999
[email protected]
www.stratec.com
---------------------------------------------------------------------------
14.03.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: STRATEC Biomedical AG
Gewerbestr. 37
75217 Birkenfeld
Germany
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: [email protected]
Internet: www.stratec.com
ISIN: DE000STRA555
WKN: STRA55
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
553399 14.03.2017
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
STRATEC Biomedical AG ISIN: DE000STRA555 können Sie bei EQS abrufen
Medtech , STRA55 , SBS , XETR:SBS